$1.51
-0.08-5.03%
Last update: Nov 12, 11:11 AM
Nexalin Technology Inc
NXLNASDAQ
Nexalin Technology fell 95.8% from $37.80 to $1.59, behind the S&P 500's +11.2%. Its worst day was Jul 28 (−24.2%), and its low came Nov 5 at $1.40.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-3.90 missed the $-3.60 estimate on $18,149.00 revenue (est. $40,000.00).
−7.7% · S&P 500 0.0%
EPS of $-3.90 missed the $-3.00 estimate on $171,895.00 revenue (est. $80,000.00).
Story events cover the past 12 months · Times ET
−2.9% · S&P 500 +0.6%
EPS of $-3.30 missed the $-3.00 estimate on $14,950.00 revenue (est. $15,000.00).
+3.4% · S&P 500 +0.8%
Nexalin Technology shares rose 27.1%, while the S&P 500 rose 0.7%.
+27.1% · S&P 500 +0.7%
Nexalin Technology shares fell 24.2%, while the S&P 500 rose 0.2%.
−24.2%, the year's worst day · S&P 500 +0.2%
EPS of $-3.30 missed the $-3.00 estimate on $12,161.00 revenue (est. $90,000.00).
−0.7% · S&P 500 +0.3%
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism
+79.3%, the year's best day, on 62M shares, the year's heaviest volume · S&P 500 +0.2%
Nexalin Technology shares fell 21.4%, while the S&P 500 fell 0.0%.
−21.4% · S&P 500 0.0%
Nexalin Technology closed at its lowest level of the year, 96.3% below where the year started.
−10.3% · S&P 500 −4.4%
Where it ended: a close of $1.59 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-2.91, revenue est. $76,000.00).
Nothing in the past 12 months.
All NXL analyst actionsNothing in the past 12 months.
All NXL dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NXL and SPY from Benzinga historical bars. Not investment advice.
